| Literature DB >> 32574284 |
Xiaofang Cai1, Yaoling Ma1, Songbo Li1, Yan Chen2, Zhihui Rong3, Wenbin Li3.
Abstract
An outbreak of the novel coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, in December 2019, which then rapidly spread to more than 80 countries. However, detailed information on the characteristics of COVID-19 in children is still scarce. Five patients with non-respiratory symptoms as the first manifestation were hospitalized from the emergency department, and were later confirmed to have COVID-19, between 23 January and 20 February 2020, at the Wuhan Children's Hospital. SARS-CoV-2 nucleic acid detection was positive for all the patients. Four of the patients were male and one was female, and their ages ranged from 2-months to 5.6 years. All lived in Wuhan. One patient had a clear history of exposure to SARS-CoV-2, one had a suspected history of exposure, while the others had no exposure history. For three of the five patients, the primary onset disease required an emergency operation or treatment, and included intussusception, acute suppurative appendicitis perforation with local peritonitis, and traumatic subdural hemorrhage with convulsion, while for the other two it was acute gastroenteritis (including one patient with hydronephrosis and a stone in his left kidney). During the course of the disease, four of the five patients had a fever, whereas one case had no fever or cough. Two patients had leukopenia, and one also had lymphopenia. In the two cases of severe COVID-19, the levels of CRP, PCT, serum ferritin, IL-6, and IL-10 were significantly increased, whereas the numbers of CD3+, CD4+, CD8+ T lymphocytes, and CD16 + CD56 natural killer cells were decreased. We also found impaired liver, kidney, and myocardial functions; the presence of hypoproteinemia, hyponatremia, and hypocalcemia; and, in one case, abnormal coagulation function. Except for one patient who had a rotavirus infection, all patients tested negative for common pathogens, including the influenza virus, parainfluenza virus, respiratory syncytial virus, adenovirus, enterovirus, mycoplasma, Chlamydia, and Legionella. Chest CT images of all the patients showed patches or ground-glass opacities in the lung periphery or near the pleura, even large consolidations. This case series is the first report to describe the clinical features of COVID-19 with non-respiratory symptoms as the first manifestation in children.Entities:
Keywords: clinical characteristics; first manifestation; non-respiratory symptoms; novel coronavirus disease 2019; pediatrics
Year: 2020 PMID: 32574284 PMCID: PMC7235428 DOI: 10.3389/fped.2020.00258
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Epidemiology and clinical characteristics of five COVID-19 cases.
| Age (y/m) | 10 m | 5.6 y | 8 m | 1.2 y | 2 m |
| Exposure history | No | Grandmother confirmed | No | No | Parents and grandparents suspected |
| First clinical manifestation | Paroxysmal crying, vomiting, currant jelly-like stool | Abdominal pain | Convulsion | Vomiting, diarrhea | Drowsiness and poor feeding, diarrhea |
| Time from illness onset to fever | 30 h | 2 days | 6 h | 5 days | — |
| Fever at presentation or prior to presentation | At presentation | No | At presentation | At presentation | No |
| Highest temperature (°C) during the course | 39.8 | 39 | 38.5 | 37.9 | — |
| Days from illness onset to admission | 1.25 | 2 | 0.25 | 6 | 3 |
| Underlying or coexisting disease | Intussusception | Acute suppurative appendicitis perforation with localized peritonitis | Traumatic brain injury | Hydronephrosis and stone in the left kidney, rotavirus infection | No |
| Complications | Shock; MODS (liver, kidney, myocardium, blood coagulation, intestinal); acute respiratory failure | No | No | Acute respiratory failure; acute heart failure; shock; MODS (liver, kidney, myocardium) | Myocardium function damaged |
| Antiviral therapy | Intravenous ribavirin, aerosol inhalation of interferon | Aerosol inhalation of interferon | Intravenous ribavirin, aerosol inhalation of interferon | Intravenous ribavirin, aerosol inhalation of interferon | Aerosol inhalation of interferon |
| Methylprednisolone | 2 mg/(kg·d) × 5d | No | No | 2 mg/(kg·d) × 3d | No |
| Intravenous immunoglobulin | 500 mg/(kg·d) × 3d | No | No | 500 mg/(kg·d) × 4d | No |
| Oxygen inhalation | Nasal cannula | No | Nasal cannula | Nasal cannula | No |
| Invasive mechanical ventilation | Yes | No | No | Yes | No |
| Blood purification | PE+CRRT | No | No | PE+CRRT | No |
| Length of stay (days) | 36 | 10 | 14 | 17 | 15 |
| Outcomes | Died | Cured | Cured | Cured | Cured |
Laboratory findings of the five cases.
| White blood cell count, × 109/L | 5.5–12 | 3.27 | 3.79 | 18.16 | 11.96 | 7.36 |
| Neutrophil count, × 109/L | 1.08–5.9 | 2.08 | 1.2 | 8.14 | 7.77 | 1.86 |
| Lymphocyte count, × 109/L | 1.15–6 | 1.06 | 2.01 | 8.93 | 2.48 | 4.2 |
| Platelet count, × 109/L | 100–378 | 29 | 247 | 386 | 184 | 338 |
| Urine analysis | PRO3+, BLD3+ | Normal | Normal | PRO±, BLD3+ | — | |
| Stool routine | Positive occult blood | Normal | Normal | Positive occult blood | Loose stool | |
| CRP, mg/L | 0–3 | 202 | 5.01 | 24.8 | 69.1 | 5 |
| PCT, ng/mL | ≤ 0.05 | >100 | 0.46 | 0.09 | 2.66 | — |
| Serum ferritin, ng/mL | 12–135 | 1179.11 | — | 30.3 | 1796.8 | — |
| IL-2 | 0–11.4 | 1.75 | — | 2.00 | 1.32 | 1.43 |
| IL-4 | 0–12.9 | 3.01 | — | 3.78 | 3.37 | 0.86 |
| IL-6 | 0–20.9 | 3868.86 | — | 70.83 | 177.86 | 7.06 |
| IL-10 | 0–5.9 | 326.93 | — | 6.68 | 26.85 | 8.45 |
| TNF-α | 0–5.5 | 2.15 | — | 2.08 | 3.52 | 1.01 |
| IFN-r | 0–17.3 | 16.98 | — | 3.74 | 2.26 | 8.35 |
| Albumin, g/L | 35–50 | 20.9 | 46.7 | 41.2 | 31.8 | 39.1 |
| Alanine aminotransferase, U/L | 9–52 | 375 | 20 | 50 | 54 | 21 |
| Aspartate aminotransferase, U/L | 15–46 | 1,093 | 31 | 50 | 124 | 46 |
| Blood urea nitrogen, mmol/L | 2.5–6.1 | 22.84 | 5.94 | — | 15.91 | 2.00 |
| Creatinine, μmol/L | 46–92 | 206.3 | 24.5 | — | 224.5 | 17.7 |
| K+ | 3.5–5.1 | 3.49 | 4.05 | 4.09 | 5.46 | 4.59 |
| Na+ | 137–145 | 133.6 | 138.2 | 136.6 | 129.2 | 136.9 |
| Cl− | 98–107 | 104 | 100.1 | 98.7 | 94.7 | 97.3 |
| Ca2+ | 2.1–2.55 | 1.32 | 2.39 | 2.27 | 1.87 | 2.55 |
| Lactate dehydrogenase, U/L | 161–371 | 3,171 | 242 | 363 | 751 | 562 |
| Creatine kinase, U/L | 30–170 | 20,702 | 84 | 107 | 177 | 97 |
| Creatine kinase—MB, U/L | 0–24 | 840 | 14 | 41 | 98 | 90 |
| Troponin (ng/mL) | 0–0.014 | 0.007 | — | 0.01 | 0.272 | — |
| NT-proBNP (pg/mL) | 0–300 | >9,000 | — | 395 | >9,000 | — |
| PT, s | 10.2–13.4 | 22.1 | 11 | 11.2 | 14.3 | 9.6 |
| APTT, s | 25.7–39 | 76 | 30.3 | 31 | 31.8 | 47.7 |
| Fibrinogen, g/L | 2–4 | 3.08 | 2.1 | 2.89 | 2.47 | 2.45 |
| D-dimer, mg/L | 0–0.55 | 40.34 | — | — | — | 1.18 |
| CD3+T | 805–4459 | 268 | — | 5,643 | 705 | — |
| CD8+T | 314–2080 | 102 | — | 1,869 | 318 | — |
| CD4+T | 345–2350 | 155 | — | 3,110 | 342 | — |
| CD16+CD56 NK | 210–1514 | 11 | — | 1,695 | 6 | — |
| CD19+B | 240–1317 | 820 | — | 9.21 | 1,180 | — |
| CD4+/CD8+T (Th/Ts) | 0.96–2.05 | 1.52 | — | 1.66 | 1.07 | — |
| Common pathogens | Neg | Neg | Neg | Rotavirus | Neg | |
CRP, C-reactive protein; PCT, procalcitonin; PT, prothrombin time; APTT, activated partial thromboplastin time; IL, interleukin; NK, natural killer.
Figure 1Chest CT images for case 1 showing a small dense shadow in the left lung on day 4 after symptom onset (A,B); bilateral ground-glass opacity, large consolidation, and bilateral pleural effusion on day 9 after symptom onset (C,D).
Figure 2Chest CT images for case 2 showing a round-like mass shadow in the dorsal segment of the lower right lobe with a slight ground-glass opacity on the edge, a strip shadow in the local area of the left lower lobe, and an arc dense under the bilateral pleura on day 3 after symptom onset (A–D).
Figure 3Chest CT images for case 3 showing a patchy dense shadow in the posterior part of the left lung with a blurred boundary on day 2 after symptom onset (A,B).
Figure 4Chest CT images for case 4 showing a large dense shadow with some consolidation in the right lung and a few high-density shadows in the upper lobe of the left lung on day 6 after symptom onset (A,B) and patchy dense shadows mixed with ground-glass opacity in the bilateral upper lobe tip, right middle lobe, and left lower lobe, and air bronchogram inside on day 15 after symptom onset (C,D).
Figure 5Chest CT images for case 5 showing bilateral scattered spots of shadows and consolidation in the upper right lobe on day 3 after symptom onset (A,B).